Outcome of the Board Meeting held on 14th November, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Citichem India Ltd's Board, at its meeting on 14th November 2025, approved the unaudited financial results for the half year ended 30th September 2025. Total revenue surged to Rs. 10.77 crore from Rs. 1.67 crore in the same period last year (over 6x growth), driven by revenue from operations of Rs. 8.52 crore. Profit after tax rose to Rs. 68 lakh from Rs. 12.25 lakh, with EPS improving to Rs. 1.36 from Rs. 0.25. The Board also approved issuing up to 47 lakh convertible warrants at Rs. 29 per warrant (face value Rs. 10), aggregating to Rs. 13.63 crore, on a preferential basis to promoters and others, subject to shareholder and regulatory approvals. The warrants are convertible within 18 months and supersede an earlier preferential issue approved at the September 2025 AGM.
The sharp revenue and profit growth signals strong business momentum and may be viewed positively by investors. The Rs. 13.63 crore preferential issue is largely promoter-led (about 91% of warrants go to MD Arif Esmail Merchant and Hashim Arif Merchant), which shows promoter confidence but will lead to equity dilution upon conversion. Shareholders' approval will be sought at an upcoming EGM.